Integration of cardiovascular risk assessment with COVID-19 using artificial intelligence

Jasjit S. Suri, Anudeep Puvvula, Misha Majhail, Mainak Biswas, Ankush D. Jamthikar, Luca Saba, Gavino Faa, Inder M. Singh, Ronald Oberleitner, Monika Turk, Saurabh Srivastava, Paramjit S. Chadha, Harman S. Suri, Amer M. Johri, Vijay Nambi, J. Miguel Sanches, Narendra N. Khanna, Klaudija Viskovic, Sophie Mavrogeni, John R. LairdArindam Bit, Gyan Pareek, Martin Miner, Antonella Balestrieri, Petros P. Sfikakis, George Tsoulfas, Athanasios Protogerou, Durga Prasanna Misra, Vikas Agarwal, George D. Kitas, Raghu Kolluri, Jagjit Teji, Michele Porcu, Mustafa Al-Maini, Ann Agbakoba, Meyypan Sockalingam, Ajit Sexena, Andrew Nicolaides, Aditya Sharma, Vijay Rathore, Vijay Viswanathan, Subbaram Naidu, Deepak L. Bhatt

Research output: Contribution to journalReview articlepeer-review

31 Scopus citations


Artificial Intelligence (AI), in general, refers to the machines (or computers) that mimic "cognitive" functions that we associate with our mind, such as "learning" and "solving problem". New biomarkers derived from medical imaging are being discovered and are then fused with non-imaging biomarkers (such as office, laboratory, physiological, genetic, epidemiological, and clinical-based biomarkers) in a big data framework, to develop AI systems. These systems can support risk prediction and monitoring. This perspective narrative shows the powerful methods of AI for tracking cardiovascular risks. We conclude that AI could potentially become an integral part of the COVID-19 disease management system. Countries, large and small, should join hands with the WHO in building biobanks for scientists around the world to build AI-based platforms for tracking the cardiovascular risk assessment during COVID-19 times and long-term follow-up of the survivors.

Original languageEnglish (US)
Pages (from-to)541-560
Number of pages20
JournalReviews in Cardiovascular Medicine
Issue number4
StatePublished - Dec 2020

Bibliographical note

Funding Information:
Dr. Vijay Nambi discloses the following relationships - (i) site PI study sponsored by Merck (complete), Amgen (to start); (ii) provisional patent along with Roche and Baylor College of Medicine for the use of biomarkers in prediction of heart failure; (iii) Dr. Nambi is supported by VA MERIT grant.

Publisher Copyright:
© 2020 Suri et al. Published by IMR Press.


  • Artificial intelligence
  • COVID-19
  • Cardiovascular
  • Myocarditis
  • Non-invasive monitoring
  • Risk assessment


Dive into the research topics of 'Integration of cardiovascular risk assessment with COVID-19 using artificial intelligence'. Together they form a unique fingerprint.

Cite this